Immunotherapy

Bladder Cancer Treatment Market to Hit $11.33B by 2034

Pune, India – September 24, 2026 -- The global bladder cancer treatment market was valued at $5.13 billion in 2025 and is projected to reach $11.33 billion by 2034, expanding at a 9.2% compound annual growth rate, according to a new analysis from Maximize Market Research.

Immunotherapy and antibody-drug conjugates drive treatment shift

Adoption of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and FGFR inhibitors is accelerating across non-muscle-invasive and muscle-invasive bladder cancer segments. Pharmaceutical companies are directing R&D spend toward intravesical drug delivery, gene therapy, and biomarker-driven precision oncology to improve outcomes for recurrent and metastatic urothelial cancer patients.

NUS Magnetic Pulse Therapy Eradicates Tumors in 75% of Preclinical Trials

Singapore – September 17, 2026 -- Researchers at the National University of Singapore (NUS) have eradicated tumours in 75 per cent of tested preclinical models using pulsed electromagnetic fields (PEMFs) alone, without chemotherapy, after just four 30-minute sessions. The study, led by Associate Professor Alfredo Franco-Obregón of the NUS Yong Loo Lin School of Medicine, was published in the journal Smart Medicine on September 17, 2026.

PEMF device already cleared Phase 1 human safety trials

The same PEMF device used in the study has completed Phase 1 clinical trials, confirming its safety in humans. The NUS team is now seeking partners to fund and conduct Phase 2 efficacy trials to evaluate treatment performance in patients.